“减肥药替尔泊肽改变了我的生活！”BBC采访英国科学家使用者

Core Viewpoint - The article discusses the increasing popularity and accessibility of the weight loss drug Mounjaro, particularly in the UK, highlighting its effectiveness and the challenges faced in its distribution through the National Health Service (NHS) [5][6][7]. Group 1: Mounjaro Overview - Mounjaro, a weight loss drug, is gaining traction and is being privately sold in clinics and pharmacies [6]. - The NHS is gradually introducing Mounjaro, with a long-term plan that may take up to 12 years to meet patient demand [6][7]. - The drug is intended for individuals with a BMI over 35 and at least one obesity-related health issue, as per NICE guidelines [7]. Group 2: Patient Experiences - Alix Harvey, a 35-year-old marine biologist, reported a 25% weight loss and a decrease in BMI from 32 to 22 after using Mounjaro for six months, although she expressed concerns about weight rebound after stopping the drug [10][11]. - Jane Graham, a 60-year-old heart physiologist, is eager to use Mounjaro but is disappointed that her BMI of 30 disqualifies her from NHS coverage, fearing that waiting for treatment could be too late for her health [13][14]. - Paul, 53, and his wife have been using Mounjaro purchased from a private clinic, with his wife losing 5 stone (31.7 kg) since starting the treatment [16].